FDA In Tug-Of-War Over Generic Cozaar/Hyzaar: Apotex And Roxane Sue Agency To Block Teva's Marketing Exclusivity
Executive Summary
FDA is engaged in a heated legal battle with Apotex and Roxane over its decision to grant Teva 180-day marketing exclusivity for generic versions of Merck's hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide)